USE OF CYTOFLAVIN FOR THE COMPLEX THERAPY OF PATIENTS SUFFERING FROM THE PRIMARY OPEN-ANGLE GLAUCOMA
Authors/Creators
- 1. Doctor of Dental Medical Sciences, Associate Professor of the Department of Ophthalmology, Tashkent State Institute
- 2. Clinical resident of the Department of Ophthalmology, Tashkent State Dental Institute; Uzbekistan, Tashkent, 100047, Yashnabad district, Makhtumkuli street 103
Description
The term "glaucoma" unites a large group of eye diseases of various origins with a progradient, chronic course. The aim of this study was to study the neuroprotective effect of Cytoflavin in patients with POAG with normalized IOP based on the clinical and functional parameters of the organ of vision. Material and methods. The study involved 60 patients diagnosed with primary open-angle glaucoma (POAG) stage I, II and III. All patients were divided into 2 groups depending on the treatment received. Results. Cytoflavin has a pronounced neuroprotective effect in POAG, effectively protecting the nervous tissue and slowing down apoptosis. In addition to improving the clinical and functional indicators of the organ of vision, we noted an improvement in overall well-being, attention and overall performance in all patients. Conclusions. Analysis of the obtained results indicates a rather high clinical efficacy of Cytoflavin in the conservative treatment of patients with POAG with compensated IOP and can be recommended as a background neuroprotective therapy.